Syndax Pharmaceuticals SNDX Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's operating lease right-of-use assets in other assets?
- Syndax Pharmaceuticals (SNDX) reported operating lease right-of-use assets in other assets of $1.21M in Q1 2026.
- How has Syndax Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Syndax Pharmaceuticals's operating lease right-of-use assets in other assets decreased by 32.7% year-over-year, from $1.8M to $1.21M.
- What is the long-term trend for Syndax Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a 35.9% compound annual growth rate (CAGR), from $290K to $1.34M.